Tweets and Retweets by @AVIVA1950 and by @pharma_BI for 15th Annual Personalized Medicine Conference at Harvard Medical School – THE PARADIGM EVOLVES, November 13 – 14, 2019 • Harvard Medical School, Boston, MA
Curator: Aviva Lev-Ari, PhD, RN

Tweets and Retweets by @AVIVA1950 and by @pharma_BI for 15th Annual Personalized Medicine Conference at Harvard Medical School – THE PARADIGM EVOLVES, November 13 – 14, 2019 • Harvard Medical School, Boston, MA
Real Time Press Coverage: Aviva Lev-Ari, PhD, RN
see also,
eProceedings 15th Annual Personalized Medicine Conference at Harvard Medical School – THE PARADIGM EVOLVES, November 13 – 14, 2019 • Harvard Medical School, Boston, MA
Tweets by @AVIVA1950 and by @pharma_BI
Donald L. Siegel, Ph.D., M.D., Director, Division of Transfusion Medicine & Therapeutic Biology, Director, Clinical Cell and Vaccine Production Facility, UPenn’s Perelman School of Medicine no relations explored between Immune T cells and microbiome
Paul Stoffels, M.D., Vice Chairman, Executive Committee, Chief Scientific Officer, Johnson & Johnson Impact of Mirobiome it plays a key role in many diseases difficult to develop therapeutics derived from microbiome data
Harpreet Singh, Ph.D., CEO, Immatics T Cell peptide started 15 years ago Peptonomics, tumors of solid cancer – cell therapies selected from libraries off the shelf cells from health donors Biologics bridges tumor cells and solid cells
Donald L. Siegel, Ph.D., M.D., Director, Division of Transfusion Medicine & Therapeutic Biology, Director, Clinical Cell and Vaccine Production Facility, UPenn’s Medicine CAR-T therapy started the Transfusion Medicine & Therapeutic Biology industry
Paul Stoffels, M.D., Vice Chairman, Executive Committee, Chief Scientific Officer, Johnson & Johnson Combination therapy emerges, MOA partnerships: cell therapy can transform cancer treatment INFECTIOUS disease had Global impact need stop the virus
Paul Stoffels, M.D., Vice Chairman, Executive Committee, Chief Scientific Officer, Johnson & Johnson Goals of medicine in 2019 early detection Vaccines in disease prevention Longevity
Joseph B. Martin, M.D., Ph.D., Dean Emeritus
fascinating personal history story on development of interest in genetic analysis
Michael J. Pellini, MD Diagnostics Pain management Patients can fight more broadly F for sharing data and data exchange 80% patients do not access Academic Centers for treatment
Michael J. Pellini, MD surgery, chemo, radiation – cost, harmful, INEFFECTIVE, Dr. Reza Columbia Medical School Oncologist 35 years How are we doing with technology? Very remarkable Clinical Utility to the Payer Regulatory – a super star in ten years
Stephen L. Eck, Carl June, UPenn Beyond Cancer: Chronic diseases have systemic of specific immune or autoimmune components: CNS, neurodegenerative and Diabetes, Sickle cell anemia – treatment by cell therapy microphages
Stephen L. Eck, Carl June, UPenn Cost of cell transfection therapy: Cost of Goods, Cost of Labor – pay for performance, Manufacture in NJ shipped to Europe – not effective
Stephen L. Eck, Carl June, UPenn Similarity between Transfusion Medicine industry and Cell therapy – Transfection of cells therapy Manufacturing of Cells for transfection: Over regulation like in small molecules vs too little regulation
Stephen L. Eck, Carl June, UPenn engineering T cells life farming – innovation is the driver, FDA is evolving in handling patents involved in Cell engineering Regulatory science needs to evolve in light of gene therapy in Human cell line in China
Stephen L. Eck, Carl June, UPenn Children vs Adults 2011 reported better results in Adults, children’s immune system is evolving In 2019 – 13 biotech companies in CAR-T cell therapies, Gene therapy is growing FDA, drug cycle T cells vs stem cells
15th Annual meeting is at a historic moment in Boston where Prof. Church launched the Human Genome Project and Eric Launder at MIT and the Cancer Genome Project. Genzyme conceived gene therapy sold to Sanofi for $ Billion Foundation Medicine
Edward Abrahams, Ph.D., President, PMC 170 drugs with biomarkers, up 15% from 2000 in Biomarker strategy Gene therapy started in 2005, today personalized medicine is becoming standard of care. Science & Technology need additional friendly environment
, &
(
) tomorrow at 9:45am ET for a panel discussion on the transformative technologies enabling #PersonalizedMedicine, at the 15th annual
Register here bit.ly/2QjhkSe#PMConf
Kenna R. Mills Shaw, Ph.D., MD Anderson Institute does not sequence genome of each patient unlike Dana Farber clinicians need to access information for decision making when disease progresses – what new test to order data sharing inside the institute
Daryl Pritchard, Ph.D., Senior Vice President, Science Policy, PMC Genomic sequencing for a single test that covers many biomarkers Improve treatment efficiency Growing recognition of the need to demonstrate value, evidence for Payers to pay
Ammar Qadan, Vice President, Global Head of Market Access, Illumina Illumina is building evidence for Harvard Pilgrim on theirs patient data on risk pregnancies Illumina is expanding building evidence for ALL rare diseases for all Test diagnostics
Roy J. Gandolfi, M.D., Medical Director, SelectHealth, UT is the Payer of Intermountain Healthcare, UT Regional approach vs National perspective medical policies requires experts for Payer to approve a treatment Consumer in the health plan
Lincoln Nadauld, M.D., Ph.D., Chief, Precision Health, Intermountain Healthcare, UT Precision Oncology Program: Need, study, analysis outcome, publish dataPharmacogenetics testing will be covered for all employees & Neonatal
Peter J. Neumann, Sc.D., Tufts Medical Center clinical utility evidence of value: saving by diagnostics cost for quality cost of diagnostics cost effectiveness – characterize utility cost effectiveness – study Value to families value of knowledge
Ammar Qadan, Vice President, Global Head of Market Access, Illumina Illumina is partnering with providers and Payer Illumina & Blue Cross Blue Shield 150 Million are covered for genomics 2500 genomics test done Under utilization educate physician
Mark P. Stevenson, COO Thermo Fisher Scientific Context: Therapy selection in personalized medicine navigate diagnostics in use and policies when implementations is considered Physicians need precise testing now Payers evidence of utility is needed
Mark P. Stevenson, Executive Vice President, Chief Operating Officer, Thermo Fisher Scientific Patient Outcome – Data analytics, ML, AI for genomics, proteomics, metabolomics, Tests must be precise and inform the diagnosis by diagnostics Solutions
Paul Stoffels, M.D., Vice Chairman, Executive Committee, Chief Scientific Officer, Johnson & Johnson Passion of Scientists pharmaceutics development is based on insights looking into the future – important goal to solve
best conference on Personalized Medicine in 15 years eProceedings 15th Annual Personalized Medicine Conference at Harvard Medical School – THE PARADIGM EVOLVES, November 13 – 14, 2019 • Harvard Medical School, Boston, MA
Retweet by @AVIVA1950
‘s William Dalton,
,
,
‘ Anne-Marie Martin &
‘s Michael Sherman discuss how to create an ecosystem of shared value that can generate the evidence needed to advance #personalizedmedicine. #PMConf
Edward Abrahams, Ph.D., President, PMC 170 drugs with biomarkers, up 15% from 2000 in Biomarker strategy Gene therapy started in 2005, today personalized medicine is becoming standard of care. Science & Technology need additional friendly environment
, &
(
) tomorrow at 9:45am ET for a panel discussion on the transformative technologies enabling #PersonalizedMedicine, at the 15th annual
Register here bit.ly/2QjhkSe#PMConf
and moderated by
’s Jay Wohlgemuth explores employer-sponsored #genetictesting partnerships between
Life Sciences
and
Leave a Reply